Gadodiamid und Gadolinium-DTPA als intravenöse Kontrastmittel in der Computertomographie

Engelbrecht, V.; Koch, Jens‐Albrecht; Rassek, Margarethe; Mödder, Ulrich

doi:10.1055/s-2007-1015709

Cited by 14 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both arterial and venous cervical or thoracic vessels could be enhanced to 100 Hounsfield units with a bolus injection, and sufficient enhancement for diagnosis of dissections/aneurysms of arterial vessels could be achieved. Attenuation of the parenchymal organs were insufficient in all these investigations [8][9][10][11][12][13][14]; therefore, gadoliniumcontaining CM are not useful for CT examinations of these organs.…”

Section: Gadolinium-chelates and Ct In Clinical Practicementioning

confidence: 99%

“…Studies reporting experiences with gadopentetate (Magnevist) for CT examinations ml/s); cave: very short vessels up to 100 HE; parenchyma of liver duration of the bulos with short and kidney was not sufficiently enhanced time window for optimal contrasting[10] 5 0.2 mmol/kg b.w. No side effects Parenchymal enhancement did not exceed 25%, arterial enhancement peak was 75%.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Actual clinical use of gadolinium-chelates for non-MRI applications

Strunk

Schild

2004

European Radiology

View full text Add to dashboard Cite

For many years, alternatives to iodinated X-ray contrast media have been sought. Of the contrast media investigated to date, only CO(2) and the gadolinium-chelates have been shown to be viable alternatives for selected X-ray examinations. Therefore, we have reviewed the general literature and that specific for gadopentetate (Magnevist) in particular, since this agent has been studied the most. This review indicates that diagnostic CT examinations can be achieved following the intravenous administration of gadolinium-containing contrast media (CM) for evaluation of aortic abnormalities. Gadolinium-containing CM at the dose approved for MR imaging are not useful for CT evaluation of the abdominal parenchymal organs. Intravenous/intraarterial injections have also been used in a variety of angiographic and interventional procedures. Image quality, however, is generally inferior to iodinated contrast media. Gadolinium-containing CM require no special handling and can be administered by hand injection or via conventional angiographic automated injectors with the same flow rates and pressures as are used with iodinated contrast media. For CT, a peripheral bolus injection of a diluted gadolinium agent (1:1 with saline) of 60-90 ml at 3-5 ml/s is usually performed. Similar to all other gadolinium-chelates, the non-MRI use of gadopentetate (Magnevist) is not approved by regulatory agencies. However, the literature suggests that a dose of 0.3-0.4 mmol/kg b.w. has been safely administered for CT as well as for angiography and interventional procedures intravenously and intraarterially. Even at this dose, though, this results in a relatively small overall volume to be injected, which limits utility somewhat.

show abstract

Section: Gadolinium-chelates and Ct In Clinical Practicementioning

confidence: 99%

mentioning

confidence: 99%

Actual clinical use of gadolinium-chelates for non-MRI applications

Strunk

Schild

2004

European Radiology

View full text Add to dashboard Cite

show abstract

“…That is why an adequate parenchymal enhancement cannot be achieved today in CT studies with i.v. administration of Gd-DTPA (5). A 1-mmoV1 solution is currently being tested for market approval and might solve this problem (6).…”

Section: Discussionmentioning

confidence: 99%

Gd-dtpa as an alternative contrast agent in conventional and interventional radiology

Vehmas

Markkola

1998

Acta Radiol

View full text Add to dashboard Cite

show abstract

“…As a consequence, it has been suggested that gadoliniumbased contrast media could be used in place of iodinated agents for radiological examinations in patients with significant renal impairment [1][2][3][4][5]. The Contrast Media Safety Committee of the European Society of Urogenital Radiology recently concluded upon an extensive review of the literature that the use of gadolinium-based contrast media for radiographic examinations to avoid nephrotoxicity in patients with renal impairment is not recommended since they are more nephrotoxic than iodinated contrast media in equivalent X-ray attenuating doses [6].…”

Section: Introductionmentioning

confidence: 99%

Gadolinium-based contrast media may be nephrotoxic even at approved doses

Thomsen

2004

Eur Radiol

100

View full text Add to dashboard Cite

It is generally believed that gadolinium-based contrast media are not nephrotoxic at the approved doses for MR (<0.3 mmol/kg body weight). Recently, a patient with diabetic nephropathy required dialysis because of anuria 6-7 days after MR angiography with 0.14 mmol/kg body weight gadolinium-DTPA-BMA to assess renal artery stenosis. No special precautions (e.g., hydration) had been taken. The serum creatinine levels had been within 200 and 300 micromol/l for the last 3 years with a very slow increase. This case highlights that gadolinium-based contrast media can cause contrast medium-induced nephropathy even at doses below 0.2 mmol/kg body weight in patients with multiple risk factors.

show abstract

Gadodiamid und Gadolinium-DTPA als intravenöse Kontrastmittel in der Computertomographie

Abstract: Sufficient parenchymal enhancement in CT studies cannot be achieved with the available gadolinium-based contrast mediums. They might be helpful if only short time vascular enhancement is required.

Cited by 14 publications

References 0 publications

Actual clinical use of gadolinium-chelates for non-MRI applications

Actual clinical use of gadolinium-chelates for non-MRI applications

Gd-dtpa as an alternative contrast agent in conventional and interventional radiology

Gadolinium-based contrast media may be nephrotoxic even at approved doses

Contact Info

Product

Resources

About